Updates on the development of Humanetics Corporation’s new drug candidate, BIO 300, were recently presented at the 2024 Military Health System Research Symposium (MHSRS) in Kissimmee, Florida.
BIO 300 was originally developed as a radioprotectant by researchers at the Armed Forces Radiobiology Research Institute (AFRRI) in Bethesda, Maryland. It was exclusively licensed to Humanetics for advanced development and commercialization. Collaborative studies continue with DOD scientists to develop BIO 300 as an oral drug that warfighters can take to provide protection against the effects of radiation from a radiological or nuclear event.
Humanetics provided an outline of clinical data supporting BIO 300’s safety and efficacy, including the proposed plan for human dose conversion under the FDA animal rule.
“Developing countermeasures that protect individuals, especially military personnel, against ARS is paramount, considering the current geopolitical environment fueling the real and increasing threat of nuclear or radiological events,” noted the press release.
The research presented was supported in part by grants from the US Department of Defense’s Congressionally Directed Medical Research Program and an Other Transaction Authority agreement with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).
In addition to applications as a medical countermeasure, BIO 300 is being evaluated in phase 2 clinical trials to prevent normal tissue injury resulting from cancer radiotherapy and to reduce inflammatory lung damage (e.g., COVID-19, Idiopathic Pulmonary Fibrosis, acute respiratory distress syndrome).
Source: Humanetics Pharmaceuticals
RELATED READING
Humanetics to develop first FDA approved drug to prevent radiation injury. Global Biodefense
BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure. Expert Opinion on Investigational Drugs
Pharmacokinetic and metabolomic studies with a BIO 300 Oral Powder formulation in nonhuman primates. Scientific Reports
The radioprotectant, BIO 300, protects the lungs from total-body irradiation injury in C57L/J mice. BioOne Digital Library
Microbiome study in irradiated mice treated with BIO 300, a promising radiation countermeasure. Animal Microbiome
Multicenter Phase 1b/2a clinical trial of radioprotectant BIO 300 oral suspension for patients with non-small cell lung cancer receiving concurrent chemoradiotherapy. International Journal of Radiation Oncology